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ABSTRACT 
Travis Joe Whitley: INVESTIGATION OF THE METHYLATION STATUS OF FGF2 
GENE IN PERIODONTAL TISSUES AS DETERMINANTS OF HEALING 
RESPONSE AFTER IMPLANT SURGERY  
(Under the direction of Silvana Barros) 
 
 Periodontal wound healing is a complex process involving a series of interactions 
of growth factors, including FGF-2. Previous studies have suggested that the FGF2 gene 
may be down-regulated in diseased periodontal tissues. Aberrant gene expression in 
smokers and diabetics has also been reported. The aims of this study were to determine 
the association of FGF2 methylation level with wound healing after implant surgery and 
the association of smoking and diabetes with FGF2 methylation. Thirty-four included 
subjects were distributed into control, smoking and diabetic groups. During the implant 
surgery, gingival tissue biopsies were collected for real-time PCR analysis. This study 
demonstrated that FGF-2 hyper-methylation and associated gene down-regulation were 
associated with smoking status and diabetes.	
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INTRODUCTION AND BACKGROUND 
Osseointegration and Dental Implant Wound Healing 
 Wound healing involves a series of complex events that are coordinated and 
sequential. Many cells, signaling pathways, and growth factors play integral roles in this 
process with precise coordination. In implant bone healing, these processes lead to 
osseointegration; the direct structural and function connection between ordered, living 
bone and the surface of a load-carrying implant (Brånemark 1983). Animal and human 
studies have demonstrated the timeline of events that occur following surgical placement 
of a dental implant (Berglundh 2003; Lang 2011).  Four phases are seen in the implant 
healing process that correlates with similar soft tissue healing events: hemostasis, 
inflammation, proliferation, and remodeling. Briefly, 2 hours after implant installing, red 
blood cells and inflammatory cells dominate the space between implant threads. The 
implant is stabilized by contact between the adjacent osteotomy bony walls and threads 
of the implant. After 4 days, fibroblasts and new blood vessels filled the area with 
osteoclastic activity seen on the old bone. One week showed the presence of new bone 
formation on the implant surface. Two weeks marked the presence of woven bone 
formation with bridging between the parent bone and implant surface occurring at 4 
weeks. At six weeks, the remodeling phase had begun with the formation of primary and 
secondary osteons (Lang 2011).  During both the inflammatory and proliferative phases, 
release of growth factors such as platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF or FGF-2), and transforming growth factor are critical elements in 
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the recruitment of cells, formation of new extracellular matrix, and angiogenesis to the 
implant surface. 
Fibroblast Growth Factor -2 (FGF-2) and Wound Healing 
Fibroblast growth factor (FGF) is protein involved with many aspects of wound 
healing. FGF was isolated completely in 1974 from bovine pituitary glands 
(Gospodarowicz 1974). FGF exists in two different isometric points, 1 and 2. While one 
was known as the acidic FGF (aFGF) or FGF1, the other became known as the basic FGF 
(bFGF) or FGF-2 (Bohlen et al. 1984). The entire nucleotide sequence of human FGF-2 
was isolated two years later (Abraham et al. 1986).  
As a member of the heparin-binding growth factor family, FGF-2 is found in 
various body tissues and exerts a range of biological effects on cells from different 
embryological origins. It acts as a potent angiogenic molecule in vivo and in vitro, aiding 
in wound healing and facilitating events necessary for re-vascularization. During this 
process, it causes proliferation of macrophages and other cell types involved in repair 
(Bikfalvi et al. 1997, Lee et al. 2010).  
FGF-2 has also been shown to play an important role in development, repair and 
regeneration of periodontal tissues (Lee et al. 2010, Murakami 2011). FGF-2 is secreted 
by macrophages and endothelial cells during the process of wound healing. During the 
proliferative healing phase, FGF-2 stimulates migration and proliferation of endothelial 
cells. In addition to producing collagen, FGF-2 differentiates myofibroblasts to induce 
wound contraction. Deposition of extra-cellular matrix components and production of 
collagen are also key roles played by FGF-2. While promoting angiogenesis, FGF-2 
exhibits potent mitogenic ability on mesenchymal cells within the periodontal ligament 
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(Murakami et al. 1999). During the bone remodeling phase, it can stimulate migration of 
mesenchymal progenitor cells which ultimately differentiate into osteoblasts and 
cementoblasts (Murakami et al. 1999). 
Several animal (Murakami et al. 1999, Murakami et al. 2003, Takayama et al. 2001) 
and human (Kitamura et al. 2008, Kitamura et al. 2011, Kitamura et al. 2015) studies 
have shown promising results in the use of FGF-2 for periodontal regeneration. In 1999, 
Murakami surgically created 2- and 3-wall intrabony defects along with Class II furcation 
defects in beagle and primate models. Six to eight weeks following surgical access and 
topical application of recombinant FGF-2, significantly greater cementum, periodontal 
ligament and bone formation was seen in the FGF-2 sites compared to control sites. 
Histological evidence of regeneration was also portrayed in this study. Epithelial down 
growth, ankylosis or root resorption were not observed in FGF-treated sites (Murakami et 
al. 1999). In 2001, another animal study was conducted by Takayama on non-human 
primates. Surgically-created Class II furcation defects were treated with either 0.1% 
human recombinant FGF-2, 0.4% rhFGF-2, carrier alone or no treatment. Their results 
demonstrated a significant increase in periodontal regeneration clinically and 
histologically with the higher dose (0.4%) of rhFGF-2 compared to other treatment 
groups (Takayama et al. 2001).  In 2003, Murakami surgically created Class II furcation 
defects in beagle dogs and treated with rhFGF-2 compared with control sites. 
Histomorphometrically, greater amounts of new cementum and bone formation, along 
with creation of PDL fibers was found compared to the control sites (Murakami et al. 
2003).  
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In 2008, a Phase II randomized, controlled, double-blind clinical trial was 
conducted by Kitamura at 13 study facilities with 74 subjects.  These subjects presented 
with 2- or 3-wall vertical bone defects and randomly assigned to four treatment groups: 
carrier alone, carrier + 0.03% FGF-2, carrier + 0.1% FGF-2, or carrier + 0.3% FGF-2. 
The results demonstrated a significantly greater rate of increase in alveolar bone height 
between the group with 0.3% FGF-2 compared to the carrier alone group at 36 weeks. No 
differences were noted for clinical attachment level or alveolar bone gains between 
groups (Kitamura et al. 2008). Three years later, the group performed a subsequent larger 
clinical trial which involved 253 patients. In this study, 200µL of 0%, 0.2%, 0.3% or 
0.4% FGF-2 was administered to 2- or 3-walled bony defects at the time of a modified 
Widman flap surgery. All FGF-2 sites demonstrated significant higher percentage of bone 
fill at 36 weeks (Kitamura et al. 2011).  
In 2015, Kitamura again published results on two randomized, placebo-controlled 
clinical trials comparing rhbFGF-2 and enamel matrix derivative (EMD) in periodontal 
regeneration for infrabony defects. The first study included 323 subjects who randomly 
received 0.3% FGF-2 or placebo during flap surgery. At 36 weeks, a significantly greater 
percentage of bone fill was seen for the FGF-2 group vs placebo (37% vs 21.5%). The 
second study included 264 subjects randomly assigned to receive either 0.3% FGF-2, 
EMD, or flap alone for treatment of infrabony defects. At 36 weeks, linear alveolar bone 
growth for the FGF-2 and EMD groups were 1.93 and 1.36 mm, respectively, which was 
statistically significantly different. 
While FGF-2 has been shown to significantly increase regeneration of periodontal 
tissues in vitro and in vivo, scarce data exists on its role in subjects with diabetes. 
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Recently, Bizenjima published an animal study on the healing of surgical periodontal 
defects in diabetic rats treated with FGF-2. The group created defects on maxillary first 
molars, which were treated with either a control carrier or FGF-2. Histological and 
radiographic analyses at 2 and 4 weeks showed a significant increase in bone volume and 
trabecular patterns for the FGF-2 group vs the control group (Bizenjima, 2015). 
Role of FGF-2 and Bone Healing 
While FGF-2 is well known for its role in angiogenesis, several studies have also 
identified a role for it in osteogenic pathways (Marie, 2003). The growth and function of 
mesenchymal stem cells from bone marrow seems to be stimulated by FGF-2 (Murikami 
2011). FGF-2 plays a key role in not only cell recruitment and proliferation in the area of 
injury, but differentiation of osteoblastic cell lineages to induce bone formation. FGF-2 
null mice have been show to demonstrate low bone mass and decreased bone formation 
as they age (Montero 2000, Behr 2010). Evidence reveals that FGF-2 has a significant 
impact in bone formation and remodeling by upregulation of the RANK – RANKL 
pathway (Fei, 2013). FGF-2 has also been shown to have positive effects on bone fracture 
healing. Animal and human studies have demonstrated that with increasing doses of 
FGF-2 applied to long bone fractures, an increase in osteocytes, bone mineral density, 
and bone repair is seen (Kawaguchi 1994, Furuya 2014, Tanaka, 2012). Mutations in 
FGF receptors have been associated with a number of craniofacial disorders, including 
achondroplasia and craniosynostosis. These processes are important events in the healing 
after dental implant placement and can greatly impact osseointegration. Recently, a 
beagle dog model was used to study the effect of FGF-2 application on implant 
osseointegration. Histomorphometry was used to examine the new bone area and bone-
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to-implant contact (BIC) at 4, 8, and 12 weeks. The study demonstrated that FGF-2 
application around dental implants significantly increased the bone area and BIC at 4 
weeks compared to control implants. Implant stability quotient (ISQ) measurements were 
also obtained with significantly higher values for the FGF-2 group at 4, 8, and 12 weeks 
compared to controls (Nagayasu-Tanaka 2016).  
DNA Methylation – An Overview 
The term “epigenetics” was first used by Conrad H. Waddington, a developmental 
biologist and evolutionist, in the middle of the twentieth century to describe heritable 
changes in patterns of gene expression without changes in the DNA sequence (Barros & 
Offenbacher 2009). He stressed that phenotype was a product of an interaction between 
the organism’s genetic sequence and its environment. Epigenetics refers to events which 
chemically modify certain DNA regions, leading to alteration of the chromatin and 
ultimately silencing or activation of a gene (Gomez et al. 2009). Various mechanisms of 
epigenetic alterations were discovered in the past half century including DNA 
methylation, post-translational histone modifications, or chromatin structural changes. 
Among them, DNA methylation is the most extensively studied mechanism in mammals 
(Barros & Offenbacher 2009).  
DNA methylation occurs when a methyl group binds to a cytosine residue within 
the cytosine-guanine dinucleotide (CpG) regions (Barros & Offenbacher 2009, Gomez et 
al. 2009, Barros & Offenbacher 2014). Methylated CpG regions interfere with the access 
of transcription factors to the promoter region, thereby silencing the gene (Barros & 
Offenbacher 2009 and 2014, Wilson 2008) (Figure 1). This DNA methylation 
phenomenon has important regulatory functions in controlling normal cellular processes. 
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During corneal wound healing, hyper-methylation of the maspin gene promoter causes 
down-regulation of maspin synthesis in corneal stromal cells, enabling these cells to 
undergo phenotypic changes to fibroblasts and myofibroblasts (Horswill et al. 2008). In 
the periodontal ligament of aged individuals, the decreased expression of collagen α1(1) 
gene is associated with elevated levels of methylation at most CpG sites in the proximal 
and distal regions of the promoter (Ohi et al. 2006).    
 
Figure 1. The DNA Methylation Process (adapted from Barros & Offenbacher 2009 
and reproduced with permission).  
 
In addition to physiological responses, DNA methylation has also been 
demonstrated to play a role in pathological cellular processes. Alteration in the 
methylation status at the promoter region of tumor suppressor genes was demonstrated to 
have an association with cancer (Wilson 2008). Persistent periodontal inflammation can 
also cause DNA methylation, which inactivates suppressors of cytokine signaling, 
resulting in exaggerated cytokine production. This lack of suppression renders an 
individual susceptible the development of a proinflammatory state, increasing the risk for 
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periodontitis (Gomez et al. 2009). In our laboratory, we discovered that chronic 
periodontal disease is associated with increased DNA methylation of the prostaglandin-
endoperoxide synthase-2 (PTGS2 or COX2) promoter, resulting in dampening of COX2 
expression. The methylation level of the PTGS2 promoter from diseased gingival 
biopsies demonstrated a 5.06-fold increase when compared with non-diseased samples (p 
= 0.03) (Zhang et al. 2010).  
Although DNA methylation has been identified as important components in various 
physiological and pathological processes, its role in periodontal wound healing has not 
yet been investigated.   
Smoking and Its Effect on the Periodontium 
According to the National Health Interview Survey performed by the U.S. Census 
Bureau in 2014, 17% of the US adult population was current smokers (CDC 2015). The 
detrimental effects of smoking on systemic health are widely known. Smoking is a major 
risk factor for heart attacks, strokes, chronic obstructive pulmonary diseases, emphysema 
and cancer. 
The adverse effects exerted by smoking on periodontal health have been 
demonstrated by compelling evidence. Locally, smoking causes a reduction in the 
gingival blood flow, thereby reducing the number of circulating leukocytes and the 
amount of oxygen reaching the gingiva (Giannopoulou et al. 1999). Systemically, 
smoking reduces serum immunoglobulin G production (Johnson & Guthmiller 2007) and 
inhibits chemotactic and phagocytic activities of peripheral blood neutrophils 
(Giannopoulou et al. 1999, Palmer et al. 2005). These actions locally reduce the 
inflammatory host responses.  
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Nicotine, a cytotoxic and vasoactive substance present in cigarette smoke, 
contributes to most of the negative effects caused by smoking. In addition to those 
already mentioned, it has been shown to inhibit the proliferation and attachment of PDL 
fibroblasts, as well as alkaline phosphatase production in cultures (Giannopoulou et al. 
1999). Reduced collagen production and increased collagenase activity in gingival 
fibroblast cultures exposed to nicotine has been demonstrated (Tipton & Dabbous 1995). 
The production of superoxide anion and hydrogen peroxide by neutrophils is inhibited by 
smoking. Oxygen uptake by neutrophils and release of superoxide and IL-1β by 
monocytes in vitro is decreased in smokers (Palmer et al. 2005, Pabst et al. 1995). 
Smoking also stimulated osteoclastic differentiation in a porcine marrow cell model 
(Henemyre et al. 2003), impaired angiogenesis in rats (Pinto et al. 2002), inhibited 
expression of various growth factors in rabbits (Theiss et al. 2000) and elevated 
production of inflammatory cytokines in humans (Tymkiw et al. 2011).     
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Table 1. Proposed Mechanisms for the Negative Periodontal Effects of 
Smoking (adapted from Johnson & Guthmiller 2007 and reproduced with permission) 
 
Proposed Mechanisms for the Negative Periodontal Effects of Smoking 
- Decreased immunoglobulin G2 production 
- Chronic reduction in blood flow and vascularity 
- Increased prevalence of potential periodontal pathogens 
- Shift in neutrophil function towards destructive activities 
- Negative effects on cytokine and growth factor production 
- Inhibition of fibroblast growth, attachment and collagen production 
 
Smoking is a well-established risk factor for periodontitis. Its relationship with 
periodontitis was examined in the Third National Health and Nutrition Examination 
Survey (NHANES III) (Tomar & Asma 2000). In this large-scale epidemiological study, 
12,329 U.S. adults were included. Results found that current smokers were 4 times as 
likely as never smokers to have periodontitis, and 42% of periodontitis cases (6.4 million 
cases) were attributable to current smoking. Smokers have also been shown to have 
reduced alveolar bone height, increased interproximal bone loss, increased attachment 
loss, higher number of missing teeth, increased probing depths and fewer sites with 
bleeding on probing compared to non-smokers (Bergstrom et al. 1991, Haffajee & 
Socransky 2001, Bergstrom 2004, Machuca et al. 2000, Natto et al. 2005, Rosa et al. 
2008).  
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Smoking also has a negative impact on outcomes of periodontal therapy. A meta-
analysis  evaluated the effect of smoking on non-surgical therapy and found that probing 
depth reduction was significantly reduced in smokers compared with non-smokers 
(Labriola et al. 2005). A review of various forms of periodontal surgical therapies 
indicated that smokers exhibited only 50-75% as much improvement in probing depth 
and attachment level as non-smokers (Johnson & Guthmiller 2007). These sub-optimal 
therapeutic outcomes are likely attributable to the compromised healing response seen in 
smokers. 
Smoking can increase the risk of failure or complications in implant therapy. Based 
on a review article, smokers were found to have at least twice the implant failure rate 
compared to non-smokers. The survival rates were summarized to be 80-100% and 93-
98% for smokers and non-smokers respectively (Johnson & Guthmiller 2007). However, 
majority of these studies were retrospective in nature. In 2007, a meta-analysis evaluating 
the effect of smoking on implant failure showed a significantly enhanced risk for implant 
failure among smokers with an overall odds ratio of 2.25 (Strietzel, 2007). Another 
review in 2009 showed a 3.6 to 4.6 increased risk of peri-implantitis in smokers 
compared to non-smokers (Heitz-Mayfield, 2009). 
The benefits of smoking cessation have been demonstrated for non-surgical 
periodontal therapy (Chambrone, 2013), periodontal health (Fiorini, 2014) and risk of 
implant failure (Bain, 1993, 1996). In 2013, Chambrone et al, published a systemic 
review and meta-analysis on the effects of smoking cessation on the outcomes of non-
surgical periodontal therapy. In the limited number of studies included, an improvement 
in clinical attachment levels following treatment could be seen. The authors concluded 
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that a benefit to smoking cessation was seen and outcomes following treatment in 
patients who stopped smoking were improved. In a systematic review, Fiorini et al, found 
that in patients who quit smoking, less progression of clinical attachment loss, a decrease 
in radiographic bone loss and periodontal probing depths could be seen during the course 
of periodontal treatment and maintenance (Fiorini, 2014).  
Some studies have demonstrated a relationship between smoking cessation and 
dental implant failures. A significantly greater number of implant failures were seen in 
smokers than in non-smokers (11.3% vs 4.8%) in a study of over 2,000 Brånemark 
implants over a 6-year period (Bain, 1993). A follow-up study of a cessation protocol 
where patients quit smoking 1 week prior and 8 weeks following dental implant 
placement was also completed by the same author. Bain demonstrated a significantly 
lower failure rate for those who followed the protocol compared to those who continued 
to smoke (11.8% vs 38.5%) (Bain, 1996). It is important to note that the implants used in 
the two previous studies were machined surface implants. Several studies have 
demonstrated no significant difference between implant failures in smokers vs non-
smokers when roughened surface implants are placed (Kumar, 2002; Balshe, 2008; 
Chambrone, 2014); however, cigarette smoke and its components negatively impact 
wound healing, which can affect outcomes of periodontal and dental implant therapy and 
cessation should be discussed and implemented when possible. 
DNA Methylation and Smoking 
The majority of studies on this topic focused on the impact of smoking on gene 
methylation in bronchial or lung tissues in lung cancer patients (Belinsky et al. 2002, 
Soria et al. 2002, Divine et al. 2005, Liu et al. 2007, Han et al. 2009, Tekpli et al. 2011). 
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Most of these studies demonstrated a positive correlation between cigarette smoking and 
abnormal promoter methylation patterns. Recently, Zhang performed a meta-analysis on 
the association between smoking and p16INK4α methylation in surgically resected tumor 
tissues from non-small cell lung carcinoma (NSCLC) patients. Nineteen cross-sectional 
studies were evaluated. The group found an odd ratio of 2.25 (CI = 1.81 – 2.80) of 
p16INK4α methylation in NSCLC patients with smoking habits compared to those who did 
not smoke. This positive association was even stronger in an Asian population (Zhang et 
al. 2011). In a separate study, Murphy investigated the relationship between in utero 
exposure to cigarette smoking, DNA methylation and birth weight of infants in 418 
pregnant women. Results showed that approximately 20% of smoking-related low birth 
weight in male infants was mediated by DNA methylation at the insulin-like growth 
factor-2 differentially methylated region (Murphy et al. 2011).  
To date, there are only two studies that have investigated the impact of smoking on 
the DNA methylation status of the periodontal tissues. Both of them were conducted on 
patients with chronic periodontitis. The first study analyzed the methylation status in the 
IL-8 gene promoter in oral mucosal cells from 41 healthy non-smokers, 30 smokers with 
chronic periodontitis and 40 non-smokers with chronic periodontitis (Oliveira et al. 
2009). The second study analyzed the methylation status in the promoter region of the 
toll-like receptor TLR2 and TLR4 genes in gingival tissues from 11 healthy non-smokers, 
11 smokers with chronic periodontitis and 12 non-smokers with chronic periodontitis (De 
Oliveira et al. 2011). In both studies, smokers were defined as a subject who consumed at 
least 5 cigarettes per day for a minimum of 5 years. Unlike the previous studies on lung 
cancer, however, neither of them succeeded in demonstrating a correlation between 
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smoking and methylation status of the gene of interest. The inconsistent results may be 
attributed to the lower smoking doses of these subjects. More investigations regarding the 
contribution of smoking to epigenetic modification in periodontal tissues are needed.  
Diabetes and Its Effect on the Periodontium 
Diabetes is a common metabolic disease that affects over 29 million Americans and 
415 million adults worldwide (ADA, 2014). Because of disturbances in insulin 
production and/or insulin resistance of cells and tissues, abnormal metabolism of sugar, 
fat and protein are seen in diabetics (Southerland 2006). The condition is associated with 
an increased incidence of hypertension, obesity, stroke, heart failure, blindness, limb 
amputations, end-stage renal disease, birth complications and sexual dysfunction (Winer 
& Sowers 2004). In 2015, the American Diabetes Association reported 12% of global 
health expenditure ($673 billion) is spent on diabetes. It was also projected that by 2040, 
1 in 10 people (642 million) will have diabetes (American Diabetic Association 2014).     
The adverse effects exerted by diabetes on the periodontium have been supported 
by consistent evidence. As early as 1967, Glickman noted delayed healing response of 
alloxan-induced diabetic rats after removing the marginal gingiva of their left maxillary 
and mandibular incisors (Glickman 1967). Devlin noted that ten days after molar 
extraction in diabetic rats, the formation of collagen in extraction sockets is inhibited, 
resulting in delayed wound healing and increased alveolar destruction (Devlin 1996). 
Nishimura cultured human periodontal ligament cells in mediums of different glucose 
levels. The group noted cells cultured in glucose-containing mediums underwent changes 
in morphology and experienced suppressed chemotactic response to platelet-derived 
growth factor (Nishimura 1996). Desta created surgical wounds on the palatal gingiva of 
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type 1 and type 2 diabetic mice. The group noted the diabetic mice had less epithelial 
wound coverage, less new connective tissue formation and reduced fibroblast density five 
days after the surgery (Desta 2010). These studies demonstrated the ability of diabetes to 
compromise periodontal wound healing. 
Diabetes is a well-known risk factor for periodontal disease. In 1990, Nelson 
investigated in the rate of periodontal disease in 2273 Pima Indians with non-insulin 
dependent diabetes mellitus (NIDDM) and found it to be 2.6 times higher than those 
without (Nelson 1990). In 1991, Emrich also assessed the relationship between diabetes 
mellitus and oral health status in 1342 Pima Indians. Their results indicated that Type 2 
diabetics had an odds ratio of 2.81 for attachment loss and an odds ratio of 3.43 for bone 
loss when compared to non-diabetic subjects (Emrich 1991). In 1998, Taylor studied data 
obtained on the oral health status of 362 Gila River Indians and found the NIDDM 
subjects were at 4.23 times higher risk of alveolar bone loss (Taylor 1998). 
Taylor later performed a comprehensive review of relevant literature from 1960 to 
2001 on diabetes and periodontal diseases. Among 21 reports on patients with type 1 
diabetes, 8 reports on type 2 diabetes, 10 studies on both types of diabetes and 8 studies 
in which the type of diabetes were not specified, all except one demonstrated greater 
prevalence, extent, or severity of at least one clinical parameter of the periodontium in 
diabetic subjects. In addition, based on four of the five studies included, the review 
suggested poor glycemic control to be a significant risk factor for poor periodontal health 
(Taylor 2001). In 2006, Khader conducted a meta-analysis on 18 cross-sectional studies 
and 3 prospective cohort studies. The group demonstrated that the diabetic subjects had 
more gingival inflammation and periodontal disease as measured by the mean values of 
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gingival index, probing depth and clinical attachment loss (Khader 2006). The 
relationship between diabetes mellitus and destructive periodontal disease was further 
strengthened when Chavarry performed a systematic review in 2009. Among the 49 
cross-sectional studies included in the review, 27 detected more periodontal diseases in 
diabetic subjects compared with non-diabetic subjects. A significant association was 
detected in clinical attachment level and periodontal pocket depth for type 2 diabetic 
subjects. The group concluded that type 2 diabetes should be considered as a risk factor 
of periodontitis (Chávarry 2009). Recently, Morita showed that the risk of developing 
periodontal disease was associated with HbA1c level. As the level of HbA1c increased, 
the risk of periodontitis also increased. This again confirmed the effects diabetes can 
exert on the periodontium (Morita 2012). 
Various biological mechanisms have been proposed to explain the impact diabetes 
has on the periodontium. Sustained hyperglycemia has also been demonstrated to cause 
proteins to become glycated and form advanced glycation end products (AGEs). AGEs 
often form on collagen, and this increases collagen cross-linking and formation of 
collagen macro-molecules. These macro-molecules are resistant to enzyme degradation 
(Monnier 1996). Elevated levels of MMPs have been found in the periodontium of 
diabetic patients. These MMPs can degrade the newly formed collagen (Sorsa 1992). The 
net effect of decreased collagen synthesis, increased MMP production and resultant AGE 
formation is the rapid degradation of newly formed collagen and the accumulation of 
collagen macro-molecules (Mealey 2006). These changes affect the normal homeostatic 
collagen turnover and alter the wound healing responses in the periodontium.   
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Abnormal growth and impaired regeneration of vessels have been demonstrated in 
the periodontium of diabetic subjects. AGEs have been shown to accumulate on the walls 
of blood vessels (Wautier 1998). This ultimately impairs tissue perfusion and wound 
healing. When AGEs form on collagen in bone, altered osteoblastic differentiation 
(McCarthy 2001) and diminished bone healing  can be observed (Santana2003). 
While most culture studies demonstrated bacterial compositions in periodontally 
diseased sites in both diabetic and non-diabetic patients were similar, alterations in 
immune and inflammatory responses of the host were believed to be the major cause of 
increased extent and severity of periodontal diseases in diabetic patients (Mealey 2006). 
Neutrophil adherence, chemotaxis and phagocytosis have been shown to be defective, 
resulting in decreased bacterial killing and increased periodontal destruction 
(Manouchehr-Pour 1981, McMullen 1981). On the other hand, monocytes and 
macrophages are often hyper-responsive, resulting in significant increase in production of 
pro-inflammatory cytokines and mediators (Naguib2004). Hyperglycemia has been 
observed to inhibit osteoblast proliferation and collagen production, which lead to less 
bone formation and formation of weakened bone (Lu 2003, Lu 2003, Gooch 2000). 
Finally, AGEs have been demonstrated to activate a receptor called “receptor of AGEs” 
(RAGE) on various cells (Schmidt 1996, Schmidt 1999). The AGE-RAGE interaction on 
monocytes can increase cellular oxidant stress and activate a transcription factor called 
nuclear factor kappa B (Schmidt 1996). This results in increased production of pro-
inflammatory cytokines, ultimately causing increased tissue destruction in the 
periodontium. 
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Figure 2. Possible Linkage between Diabetes and Periodontal Disease Severity 
(adapted from Southerland et al. 2006 and reproduced with permission).  
 
Similar to smoking, diabetes can increase the risk of failure of implant therapy. de 
Morais performed an animal study in which dental implants were placed in the tibia of 40 
adult rats. The group stated that diabetes impaired bone density around the implants (de 
Morais 2009). Javed and Romanos performed a systematic review of 18 studies selected 
between 1982 and 2009. They reported that implant osseointegration was negatively 
affected by poorly controlled diabetes but occurred successfully in patients with optimal 
glycemic control (Javed 2009). 
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DNA Methylation and Type II Diabetes 
Currently, no investigations have been initiated on the impact of diabetes on the 
DNA methylation status of the periodontal tissues. Only limited studies that have 
examined the relationship among epigenetic status in target tissues, insulin production 
and development of type 2 diabetes exist. One study reported that DNA methylation in 
the promoter of transcriptional co-activator, PRARGC1A, was elevated in pancreatic 
islets from patients with type 2 diabetes compared with healthy subjects. PRARGC1A 
expression was shown to correlate inversely with the degree of DNA methylation, and 
thus was reduced in pancreatic islets of diabetic patients (Ling et al. 2008). Another study 
examined the role of DNA methylation in the regulation of mouse and human insulin 
gene expression. The CpG sites in both mouse Ins2 and human INS promoters were 
found to be hypomethylated in healthy pancreatic beta cells. When these CpG regions 
were methylated, insulin promoter activity was suppressed by almost 90% (Kuroda et al. 
2009). Review articles on epigenetics in diabetic kidney disease also highlight the 
implications of DNA methylation in development of diabetes, fibroblast proliferation and 
fibrosis in injured kidneys, and vascular complications of diabetic patients (Ling & 
Groop 2009, Reddy & Natarajan 2011). Recently in 2014, Lou et. al, demonstrated that 
the expression of proinflammatory cytokines such as IL-1β, IL-6, and TNF-α in diabetic 
rat aortas was significantly higher compared to control rats (Lou, 2014). Many studies 
have demonstrated a hyperinflammatory state in diabetics that contributes to decreased 
wound healing and other complications. 
Insulin resistance, a condition often seen in type 2 diabetes, may also be related to 
DNA methylation. Zhao recently performed a twin study that examined the association 
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between global DNA methylation of Alu repeats in peripheral blood leukocytes and 
insulin resistance in 84 pairs of monozygotic twins. Results showed that methylation 
levels of all four CpG sites were individually associated with insulin resistance (p = 
0.026). Genetic factors did not confound this association. This study again confirmed the 
possible role of DNA methylation in pathogenesis of type 2 diabetes (Zhao et al. 2011).       
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AIMS 
The overall goal of this study is to identify alterations of methylation status of the 
FGF2 gene and how this methylation affects its expression after implant surgeries in 
healthy individuals, smokers and diabetics.  
The specific aims include: 
1. To determine the methylation status of the FGF2 gene and gene expression 
during wound healing after implant placement. 
2. To determine whether smoking and diabetes are associated with differential 
methylation of FGF2 gene. 
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HYPOTHESES 
It is hypothesized that the methylation status of the FGF2 gene can affect the 
level of FGF-2 secreted during wound healing phase after dental implant surgery. It is 
also hypothesized there exists a difference in methylation levels of FGF2 gene in healthy 
subjects, smokers and diabetics that can interfere with wound healing.  
23	
	
MATERIALS AND METHODS 
Study Population 
This study was approved by the Institutional Review Board at the University of 
North Carolina at Chapel Hill. Subjects of age 18 – 70 years were recruited into this case-
control study (Appendix I. Supplementary Materials and Methods). The subjects were 
placed into one of three groups according to their medical condition. Group 1 (control) 
consisted of non-smokers and non-diabetics. Group 2 (smoking category) consisted of 
smokers who were not diabetic. Group 3 (diabetic category) consisted of diabetics who 
were not smokers. The smoking group could be current smokers or former smokers who 
had quit smoking within the last 10 years. The target number of recruitment was 20 for 
the control group, 12 for the smoking group and 12 for the diabetic group. All subjects 
received at least one dental implant placement within the study time frame. Implants were 
placed as one-stage, either on edentulous ridges or in extraction sockets. Recruited 
subjects must have probing depth ≤ 4 mm or 5mm without bleeding on probing for all 
teeth in the same quadrant of implant placement. Individuals were excluded from the 
study if they had chronic disease with oral manifestations (e.g. Crohn’s disease, lupus 
erythematosus, Behcet’s disease, etc), exhibited gross oral pathology, have used 
antibiotics or NSAIDs within 2 weeks of the screening examination, have undergone 
chronic treatment (i.e. two weeks or more) with any medication known to affect 
periodontal status (e.g. phenytoin, calcium, antagonists, cyclosporine, warfarin) within 1 
month of screening examination, had systemic conditions except smoking and diabetes 
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that are known to affect the periodontal status, had active infectious diseases such as 
hepatitis A – E, HIV or tuberculosis, and were known to be pregnant or breastfeeding 
Gingival Tissue Biopsies, Gingival Crevicular Fluid (GCF) Collection and Implant 
Stability Quotient (ISQ) Measurements  
For each enrolled subject, a screening periodontal examination was performed within 
two weeks of the implant surgery or on the day of implant placement. Plaque index (PI), 
gingival index (GI), probing depth (PD), percentage of bleeding on probing (BOP %) and 
clinical attachment level (CAL) were recorded for all teeth in the same quadrant of implant 
placement. Glycosylated hemoglobin (HbA1c) levels of the diabetic study subjects were 
also measured by a DCA 2000®+ Analyzer (Bayer Inc., Toronto, ON, Canada). On the day 
of surgery and prior to implant placement, 8 GCF samples were collected from the 
mesiolingual, mesiobuccal, distolingual and distobuccal surfaces of the two teeth that are 
in the closest proximity to the implant site. GCF samples were collected using filter paper 
strips (Pro Flow, Inc., Amityville, NY). During the implant surgery of each subject, a 
gingival biopsy was obtained over the implant site using a 4mm punch biopsy blade or a 
scalpel blade and divided in half. One half of the sample was to be used for DNA 
methylation analysis, the other for mRNA gene expression analysis. Biopsy samples for 
mRNA expression were immediately placed in RNAlater® (Applied Biosystems / Ambion 
Inc., Austin, TX) overnight at 4°C and stored at -80°C 24 hours later.  Samples for DNA 
methylation were immediately stored at -80°C. One sample for mRNA expression from 
the diabetic group was lost during lab processing. 
  Study subjects returned for follow-up visits at 2 weeks, 4 weeks and 6 weeks after 
implant surgeries. GCF samples were collected from the same sites, wound healing indices 
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(WHI) as indicators of degree of soft tissue healing were recorded for the implant sites, 
and GI and PI were scored for all teeth in the same quadrant of implant placement during 
these three visits. Degree of osseointegration in terms of implant stability was measured 
using Osstell ISQ instrument (Osstell Inc., Linthicum, MD) at 4 weeks and 6 weeks after 
implant surgeries.  WHI measurements, ISQ data, and GCF samples were collected but due 
the purpose of this paper, the findings will not be presented. This data will be used for 
future analyses. 
RNA Isolation and Quantitative Real-Time Reverse Transcription PCR 
RNA was isolated from the collected gingival tissue samples using a TissueLyser 
LT (Qiagen, Valencia, CA) and a RNeasy Mini Kit (Qiagen, Valencia, CA). The RNA was 
quantified using the NanoDrop (Thermo Scientific, Wilmington, DE). For each sample, a 
volume of 300 ng of RNA was used to generate complementary DNA (cDNA) through 
reverse transcription reactions using the SuperScript® VILOTM cDNA Synthesis Kit 
(InvitrogenTM, Life TechnologiesTM, Grand Island, NY). Quantitative real-time PCR (qRT-
PCR) was performed with 2µL of synthesized cDNA, 7.5µL of Taqman® Universal PCR 
Master Mix, .75µL of Taqman® Gene Expression Assay Mix for FGF2 gene and 5.5µL of 
ddH2O in a 7000 Sequence Detection System (ABI Prism, Applied Biosystems, Carlsbad, 
CA). mRNA expression level was normalized using GAPDH as a housekeeping gene. 
DNA Isolation, Selective Digestion and Quantitative Real-Time PCR 
Genomic DNA was isolated from the collected gingival tissue samples using 
DNeasy Mini Kit (Qiagen, Valencia, CA). The DNA was quantified using the NanoDrop 
(Thermo Scientific, Wilmington, DE).  250 ng of genomic DNA isolated from gingival 
tissue samples was digested using EpiTect Methyl II DNA Restriction Kit (Qiagen Cat# 
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335452). DNA was aliquoted into four equal portions. Each portion was subjected to a 
different reaction: Mock digest (no digestion), methylation sensitive digest (digestion of 
unmethylated and partially methylated DNA only), methylation dependent digest 
(digestion of methylated DNA only), and double digest (digestion of both methylated and 
unmethylated DNA). DNA digestion was allowed to take place at 37°C for 6 hours to 
overnight. Following the digestion inactivate the enzymes at 65 ºC for 20 minutes. Digested 
DNA was then quantified by qPCR using EpiTect Methyl II PCR Primer Assay for 
Human FGF-2 (CpG Island ID: 111236, Cat #: EPHS111236-1A). qRT-PCR was performed 
using 12.5µL of RT SYBR Green qPCR Master Mix, 1µL of PCR primer mix 
for FGF2 gene (Catalogue no. MePH06727-1A, SABiosciences, Frederick, MD), 1µL 
of  each digested DNA and 10.5µL of ddH2O in a 7000 Sequence Detection System (ABI 
Prism, Applied Biosystems, Carlsbad, CA). Data analysis was done using integrated Excel-
based templates provided by the manufacturer, which provided gene methylation status as 
percentage unmethylated (UM) and percentage methylated (M) fraction of input DNA. 
Unmethylated (UM) represents the fraction of input genomic DNA no methylated CpG 
sites in the amplified region of a gene. Methylated (M) represents the fraction of input 
genomic DNA containing two or more methylated CpG sites in the targeted region of a 
gene. A relative methylation fold change to controls was reported. 
Statistical Analysis 
Chi-square test was used to compare gender and race. Fisher’s Exact Test was used 
to compare implant sites. ANOVA test was used to compare age and BMI among the 
three study groups. The ANOVA test was also applied for comparison in mRNA 
expression and DNA methylation among various groups. Linear regression was used to 
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determine the association of DNA methylation with mRNA expression. The threshold for 
statistical significant difference was set at a p-value ≤ 0.05. All analyses were performed 
with SAS (SAS Institute, Cary, NC).
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RESULTS 
Participant Recruitment Process 
From September 2010 to January 2016, a total of 236 patients attending the UNC 
Graduate Periodontal Clinic for implant placement were screened. 202 patients were not 
recruited into the study based on a variety of reasons (Table 2). A total of 34 participants 
were successfully recruited. 
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Table 2. Participant Recruitment Process 
Recruitment Process Number (%) of Subjects 
Screening 236(100.0%) 
Reason for Disqualification: 202 (85.5%) 
Ex-smoker 73 (30.9%) 
Age > Upper Limit 36 (15.3%) 
Unable to Collect Tissue Sample 24 (10.2%) 
Not interested  15 (6.4%) 
Unable to Obtain Consent 9 (3.8%) 
< 2 teeth Remained in Same Quadrant 5 (2.1%) 
Use of NSAIDs < 1 month 4 (1.7%) 
Smoking < 5 pack-years 3 (1.3%) 
Others 33 (14.0%) 
Recruited 34 (14.4%) 
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Study Population Demographics 
 The 34 recruited participants included 20 control subjects, 7 smokers and 7 
diabetics. The mean participant age varied from 47.9 to 58.9 years with a standard deviation 
ranged from 1.8 to 2.9 (Table 3). Majority of the participants were Caucasians, and more 
female participants were recruited in the control and smoking groups. BMI was recorded 
for all participants with the mean values for groups ranging from 28.3 to 33.9 kg/m2. 
Statistical significance was not found with gender and race among the three study groups; 
however, the mean age (p=0.003) and BMI (p=0.03) for the diabetic group were 
statistically significantly higher than the control group (Table 3). 
 One subject did not successfully complete the study. The subject who withdrew 
belonged to the control group. She had an implant failure at 2 weeks after the surgery, and 
the cause of failure was not contributable by the study. The implant site was grafted and 
implant placement will be reattempted in the near future. The tissue sample collected from 
this subject was used in the DNA and RNA analyses.  Tissue samples from three subjects 
were obtained and used in the DNA and RNA analyses, but the follow-up visits were not 
completed. Two of these subjects were smokers with the other being diabetic. 
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Table 3. Study Participant Demographics (Total n = 34) 
Groups 
Variables Control (n=20) N (%) 
Smoking 
(n=7) 
N (%) 
Diabetic 
(n=7) 
N (%) 
Number 20 (58.8%) 7 (20.6%) 7 (20.6%) 
Mean age (StdDev) 47.4 (1.8) 54.1 (2.9) 58.3 (2.9)* 
Gender:    
Male 8 (40%) 1 (14%) 4 (57%) 
Female 12 (60%) 4 (86%) 3 (43%) 
Race:    
Caucasian 14 (70%) 7 (100%) 5 (71%) 
African American 4 (20%) 0 2 (29%) 
Asian 1 (5%) 0 0 
Other 1 (5%) 0 0 
BMI (StdDev) 28.2 (1.3) 27.1 (2.0) 33.9 (2.0)* 
 
 
 
 
	
	
	
	
	
 
	
	
	
*p < 0.05: significantly different from control group 
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Selected Implant Sites 
The selected implant sites for participants in all 3 groups were listed on Table 4. 
Majority of implants for the control group was placed in the molar and premolar regions, 
especially in the mandibular molar area. All implants for the diabetic group were placed 
in the maxillary arch, with the majority being in the anterior sextant. No statistical 
significance was found with respect to implant site among the three study groups 
(p=0.09).  
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Table 4. Implant Sites of Study Participants (Total n = 34) 
  Groups   
Implant sites 
Control 
(n=20) 
N (%) 
Smoking (n=7) 
N (%) 
Diabetic (n=7) 
N (%) P-Value 
Maxillary 
molar 3 (15%) 1 (14.5%) 2 (28.5%) 
0.09 
Maxillary 
premolar 5 (25%) 2 (28.5%) 1 (14.5%) 
Maxillary 
anterior 1 (5%) 1 (14.5%) 4 (57%) 
Mandibular 
molar 9 (45%) 2 (28.5%) 0 
Mandibular 
premolar 2 (10%) 1 (14.5%) 0 
Mandibular 
anterior 0 0 0 
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Differential DNA Methylation of FGF2 Gene in Smokers and Diabetic Participants 
A comparison among the control subjects, smokers and diabetic participants 
indicated increased methylation of FGF2 gene was present in the smoking and diabetic 
groups (Figure 3). The percentages of hyper-methylation in the gingival tissues of the 
control, diabetic and smoking groups were 6.29±3.85, 8.92±5.64 and 16.84±5.64 
respectively. The p-values were 0.70 and 0.34 for the gingival samples from diabetics and 
smokers respectively when compared to the control samples. This indicated the 
difference in the methylation level of FGF2 gene between smoking and control groups 
was not statistically significant; however, a trend towards higher methylation of FGF2 
gene was seen for smokers and diabetics compared to controls.  
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Figure 3. Methylation Level of FGF2 Gene in Smokers or Diabetics in 
Comparison to Control Subjects. 
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Differential mRNA Expression of FGF2 Gene in Smokers and Diabetic Participants 
A comparison among the control subjects, smokers and diabetic participants 
indicated there was a down-regulation pattern of mRNA expression of FGF2 gene in the 
smoking and diabetic groups (Figure 4). The fold changes for the control, smoking and 
diabetic groups were 1.0±0, 0.59±0.23 and 0.54±0.39 respectively. In other words, the 
gingival tissues in the smoking and diabetic groups had 0.6 and 0.5-fold decrease in 
FGF2 gene expression respectively compared to gingiva from the control group. The p-
values of the corresponding comparisons for the diabetic and smoking groups were 0.03 
and 0.04 respectively, indicating the differences were statistically significant. This data 
shows a statistically significant decrease in gene expression for FGF-2 in the smoking 
and diabetic groups compared to control subjects. 
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Figure 4. Messenger Level of FGF2 Gene in Smokers or Diabetics in 
Comparison to Control Subjects
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DISCUSSION 
In this study, hyper-methylation of FGF2 gene was consistently observed in the 
gingiva from smoking and diabetic subjects relative to the gingiva from healthy subjects. 
The level of mRNA expression of the FGF2 gene is down-regulated in gingiva from 
smokers and diabetics. Overall, differential methylation patterns of the FGF2 gene 
among gingiva from healthy individuals, smokers and diabetics were associated with 
levels of FGF2 gene expression.  
Limited literature relating smoking and diabetes with DNA methylation of other 
genes could be identified. Regarding smoking, majority of studies focused on bronchial 
or lung tissues in lung cancer patients (Belinsky et al. 2002, Soria et al. 2002, Divine et 
al. 2005, Liu et al. 2007, Han et al. 2009, Tekpli et al. 2011). Most studies demonstrated a 
positive correlation between cigarette smoking and abnormal methylation patterns. In a 
meta-analysis performed by Zhang on the association between smoking and p16INK4α 
methylation in tumor cells from lung carcinoma patients, more than a 2-fold increase of 
p16INK4α methylation in NSCLC patients with smoking habits was noted. The group later 
found the association to be stronger in an Asian population (Zhang et al. 2011). Lin 
demonstrated nicotine-derived nitrosamine ketone, a cigarette smoke carcinogen, was 
capable of influencing the expression of DNA methyltransferase 1 (DNMT1) and 
ultimately leading to hypermethylation of p16INK4α in a dose-dependent manner in human
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lung tumor tissues (Lin et al. 2010). However, in two studies performed by Oliveira 
(Oliveira et al. 2009) De Oliveira et al. 2011) regarding the impact of smoking on the 
DNA methylation status of IL-8, TLR2 and TLR4 gene promoters in the periodontal 
tissues, both failed to demonstrate a correlation between smoking and methylation of 
these gene promoters. Smoking dose likely had a significant role in the inconsistent 
results. In the lung cancer study, smokers were defined as subjects who demonstrated at 
least a 5 pack-year history, but 1.25 pack-years was the threshold in Oliveira’s studies.  
Regarding diabetes, literature has also been identified. One study reported that 
DNA methylation in the promoter of transcriptional co-activator, PRARGC1A, was 
elevated in pancreatic islets from patients with type 2 diabetes (Ling et al. 2008). Another 
study demonstrated methylation of the CpG sites in both mouse Ins2 and human INS 
promoters in pancreatic beta cells suppressed the insulin promoter activity by as much as 
90% (Kuroda et al. 2009). A third study demonstrated the methylation levels of CpG sites 
in the Alu repeats of peripheral blood leukocytes were associated with insulin resistance 
(Zhao et al. 2011). Recently, Singh et. al completed a case control study analyzing 
diabetic foot ulcers from Type 2 diabetic subjects. Biopsies were taken from the wound 
margins and used for real time-PCR analysis of TLR2 and the methylation status of the 
TLR2 promoter. TLR2 mRNA expression was reduced in Type 2 diabetic foot ulcers 
compared to controls and tended to increase with the severity of the wounds. While the 
methylation status of the TLR2 gene was not significantly different for the different 
grades of wounds, the CpG sites investigated were totally or partially methylated in 
majority of the diabetic foot ulcer cases. This study concluded that TLR2 down regulation 
in diabetic subjects may lead to chronic wound development and plays a significant role 
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in wound healing (Singh, 2015). In general, existing evidence supports findings from our 
current study, that smoking and diabetes are associated with hyper-methylation pattern of 
FGF2 gene. 
A statistically significant association was not detected for DNA methylation of 
FGF2 gene in smokers and diabetics compared to control subjects; however, the smoking 
group demonstrated almost two times greater % methylation than the diabetic group. This 
can partly be explained by the severity of the systemic condition of subjects included. 
Subjects in the smoking group were mostly heavy smokers, with two being former 
smokers who had quit within the last 10 years. While the dose-response relationship 
exerted by smoking on periodontal health has been well documented in literature 
(Bergstrom et al. 1991, Machuca et al. 2000, Haffajee & Socransky 2001, Bergstrom 
2004, , Natto et al. 2005, Rosa et al. 2008), the degree of DNA hyper-methylation in the 
gingival tissues can be expected to be higher than subjects who have never smoked. The 
mean DNA methylation and gene expression could have been affected, but in a more 
significant way due to smokers having increased smoking duration, amount, and current 
smoking status. On the other hand, the diabetic subjects had HbA1C levels of 7.0% or 
less, indicating that their diabetic condition was controlled. Diabetic patients who are 
controlled have been shown to exhibit healthier periodontal status than those with poor 
glycemic control (Taylor 2001). It is reasonable to observe the increased methylation 
pattern of FGF2 gene in the gingiva of smokers, even more so than diabetics. Although 
the methylation results did not reach statistical significance, a pattern was observed. 
In the current study, the methylation of FGF2 gene in gingival samples was 
detected with the EpiTect Methyl DNA Methylation PCR system (Methyl-ProfilerTM, 
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SABiosciences Corporation, Frederick, MD). Unlike the bisulfate-based methods, this 
method detects remaining input DNA after cleavage with a methylation-sensitive and/or a 
methylation-dependent restriction enzyme. These enzymes can cleave a minimum of 
three unmethylated CpG sites and three methylated CpG sites respectively in the 
promoter region. Following digestion, the remaining DNA fragments of FGF2 gene are 
quantified by real-time PCR using primers that bind to the promoter region of interest. 
The exact number of CpG sites cleaved by each enzyme, the CpG locations on the FGF2 
gene and the sequence of the primers are proprietary to the manufactory company, and 
thus they could not be obtained for result evaluation.     
FGF-2 can up-regulate many genes and affect various downstream reactions, but 
the exact mechanisms by which the FGF2 gene is regulated remain unclear. No studies at 
the present have investigated how smoking can affect RNA expression of FGF2 gene 
during wound healing. Only one study could be identified to support the inhibitory effect 
that smoking has on the activity of FGF-2 protein. Pauwels and his group (Pauwels et al. 
2010) evaluated whether cigarette smoke triggered pulmonary and systemic pentraxin 3 
(PTX3) expression in vivo in a murine model. PTX3, a soluble pattern recognition 
receptor, is produced in response to pro-inflammatory cytokines IL-1β and TNF-α and 
mediates angiogenesis by influencing FGF-2 activity. They detected elevated levels of 
PTX3 and reduced mRNA expression of FGF2 at 4 weeks and 24 weeks after exposure 
to cigarette smoke. These findings could be related to binding of FGF-2 protein by the N-
terminal domain of PTX3, which inhibited the angiogenic activity of FGF-2. 
Potential biological mechanisms of how diabetes down-regulates FGF2 RNA 
expression have been proposed. Werner and his group (Werner et al. 1994) demonstrated 
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RNA expression of FGF2 was reduced in diabetic mice compared with normal mice 
during the period of wound re-epithelialization and granulation tissue formation. They 
stated this observation could be resulted from delayed infiltration of acute inflammatory 
cells into the wound area, impaired ability for diabetic macrophages to synthesize FGF-2, 
and reduced level of serum components in diabetic mice to induce FGF2 expression. Lu 
and his group (Lu et al. 2008) found a circulating electronegative low density lipoprotein 
(LDL) named L5 in type 2 diabetics diabetes. L5 induced endothelial cell apoptosis by 
suppressing FGF2 expression. FGF2 expression exerted most of its effects by activating 
the phosphatidylinositol 3-kinase (PI3K)-Akt pathway. Once activated by FGF2, the 
phosphorylated Akt activated endothelial nitric oxide synthase, which is essential for 
survival of endothelial cell. Lu suggested FGF-2 was auto-regulated by Akt activation 
through a positive feedback loop. They isolated L5 from type 2 diabetic patients, and 
found L5 caused reduction in Akt phosphorylation causing a decrease in the transcription 
of the FGF2 gene. He concluded that L5 could potentially impair FGF-2 dependent re-
endothelialization and could play a role in diabetes-associated wound impairment and 
atherosclerosis.   
FGF-2 plays an important role in bone formation, differentiation and metabolism 
(Marie 2003, Kawaguchi et al. 2000). It is produced by osteoprogenitor cells and mature 
osteoblasts and accumulates in bone extra-cellular matrix. Being a potent mitogen for 
mesenchymal cells, it directs these cells to commit to the osteoblastic lineage 
(Kawaguchi et al. 2000). The regulatory effects of FGF-2 on genes controlling osteoblast 
differentiation were recognized with main contribution from studies on genetically 
modified mice and human mutations. The binding of FGFs with osteoblasts induces 
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signaling pathways involving the expression of transcription factors such as Runx2 and 
AP-1 that activate downstream osteoblast differentiation genes (Marie 2003). Coffin 
(Coffin et al. 1995) discovered that over-expressing FGF-2 in mice induced abnormal 
long bone formation, and Montero (Montero et al. 2000) later noted bone formation was 
inhibited by deactivating FGF-2.  
Using Fgf2-null mice, Fei and his group (Fei et al. 2011) demonstrated a role of 
FGF2 in osteoblastogenesis through Wnt signaling. Wnts are a family of 19 glycoproteins 
secreted in mammals, and were well demonstrated to positively regulate osteoblast 
differentiation and bone formation (Krishnan et al. 2006). The group found that mRNA 
and protein expression for Wnt10b and β-catenin decreased significantly in Fgf2-null 
mice, and the addition of exogenous FGF-2 promoted β-catenin accumulation in the 
nucleus of bone marrow stromal cells while also increasing their mineralization.  
The effects of FGF-2 can be enhanced with bone morphogenetic protein-2 (BMP-
2). Rat marrow-derived mesenchymal stem cells exposed with FGF-2 and BMP-2 
induced expression of osteoclacin mRNA and formation of bone-like nodules earlier than 
either factor alone (Hanada et al. 1997). Supplementing mesenchymal stromal cell culture 
sequentially with FGF-2 before BMP-2 resulted in high ALP activity, elevated bone-
specific osteocalcin expression and abundant bone matrix formation (Maegawa et al. 
2007). Adult rabbits underwent intertransverse process fusions at L4-L5 and implanted 
with mesenchymal stem cells. Only the group with both BMP-2 and FGF-2 addition 
demonstrated bone in-growth at 6 weeks, and this group had a higher 6-week fusion rate 
than the groups with only BMP-2 or FGF-2 (Minamide et al. 2007). Recently, FGF-2 has 
been demonstrated to reduce expression of the BMP receptor 1A on murine 
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osteoprecursor cells, influencing osteoblast differentiation (Park 2011). In addition to 
BMP-2, a review written by Marie in 2003 also provided evidence to support interaction 
of FGF-2 with other biological factors, such as cAMP and TGF-β to enhance 
osteogenesis (Marie 2003).   
The ability of FGF-2 to regulate bone remodeling is supported by studies that 
demonstrated bone resorption caused by FGF-2 stimulation in cell cultures (Kawaguchi 
et al. 2000, Simmons & Raisz 1991, Kawaguchi et al. 1995, Chikazu et al. 2001). In these 
studies, FGF-2 was shown to modulate osteoclast differentiation through various 
mechanisms. The indirect mechanism involved FGF-2 activating cyclo-oxygenase 2 
(COX2) and producing prostaglandin, leading to the induction of the receptor activator of 
nuclear factor κB ligand (RANK-L) in osteoblasts (Kawaguchi et al. 2000, Kawaguchi et 
al. 1995). This effect was abolished by NSAIDs (Kawaguchi et al. 2000). On the other 
hand, the direct mechanisms involved FGF-2 binding to FGF receptor type 1, a tyrosine 
kinase receptor on osteoclasts and their precursors, to induce bone resorption and prevent 
differentiation (Kawaguchi et al. 2000, Chikazu et al. 2001) (Chikazu et al. 2001). FGF-2 
has been shown to play a key role in affecting molecular interactions and intracellular 
mechanisms in osteoblasts to induce osteoblastic differentiation and enhance 
osteogenesis. 
Several limitations can be identified in the study. 1) The principle one is the small 
sample sizes in the smoking and diabetic groups. The target number of recruitment was 
20 for the control group, 12 for the smoking group and 12 for the diabetic group; 
however, the control group was the only category that met the goal. 2) Another important 
one is the cross-sectional design used to evaluate impact of smoking and diabetes on 
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DNA methylation. 3) Smoking history and dosage were self-reported, and HbA1c was 
not evaluated in the other two non-diabetic groups. This led to reporting biases and 
potential for ex-smokers, current smokers and undiagnosed diabetics to be recruited into 
the wrong group. 4) Subjects in the smoking and diabetic groups were not stratified 
according to their smoking doses or HbA1c levels. Evaluation of dose-response 
relationships was not possible. This dosage could have impacted the amount of DNA 
methylation seen in each sample. 5) Bone structure and implant size nor surface were not 
controlled. Although all implant surfaces were roughened, a difference in surface 
modification could play a role in recruitment of growth factors, migrations of cells, and 
the rate of implant healing and osseointegration. Future investigations should 1) increase 
the sample sizes, 2) increase number of follow-up visits to assess wound healing more 
closely, 3) address causality and dose response of smoking and control of diabetes with 
DNA methylation, 4) specify the bone quality of the patients, implant type and implant 
size to be included in the study, and 5) evaluate DNA methylation, mRNA expression 
and protein expression of other biological factors such as platelet-derived growth factor, 
transforming growth factor-β or interleukin-1β.      
In conclusion, association patterns of differential methylation of FGF2 gene in 
smokers and diabetics were identified in this study. Hyper-methylation levels of FGF2 
gene coincided with down-regulation of its mRNA expression. Systemic and 
environmental factors were shown to have epigenetic effects on the expression of the 
FGF2 gene which could affect their healing response. A potential role of the epigenetic 
modification of genomic DNA in the biological process of periodontal wound healing 
was found based on the results of this study. The evaluation of DNA methylation patterns 
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of known biomarkers may allow clinicians to more predictably assess the risk and 
complications of dental implant treatment. Further studies are needed to determine the 
effect of smoking and diabetes and their impact on DNA methylation, gene expression, 
and healing of the periodontium. 
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APPENDIX I 
SUPPLEMENTARY MATERIALS AND METHODS 
Institutional Review Board, University of North Carolina at Chapel Hill 
IRB Study Number 10-1184 
1. Clinical Study Design 
This is a longitudinal case-control study of 6-8 weeks in duration. Clinical 
parameters and biological samples were collected from healthy subjects, smokers and 
diabetics during the course of implant therapy. The study was performed in a single 
masked or blinded manner. All laboratory assessments were performed without 
knowledge of the subjects’ type of treatment and health condition.  
2. Human Subjects 
Subjects were recruited from the Graduate Periodontology clinic in the School of 
Dentistry of University of North Carolina. All subjects had at least one implant placement 
in their treatment plan that was set up in the Graduate Periodontology clinic. They were 
placed into one of three groups according to their smoking and diabetic statuses. Group 1 
(control) consisted of subjects who have never smoked and who were never diagnosed 
with diabetes. Group 2 (smoking category) consisted of subjects who were currently 
smoking and had at least 5 pack-year of smoking history, but were never diagnosed with 
diabetes. Group 3 (diabetic category) consisted of subjects who have never smoked, but 
were currently being treated with medications and/or insulin for type II diabetes. All 
subjects had healthy periodontium. Smoking history and diabetic status were self-
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reported. The level of control of the diabetic condition was confirmed by HbA1c test 
within 3 months prior to screening. Screening and follow-up examinations were 
performed in the General Oral Health Center in the School of Dentistry. Implant surgery 
was performed in the Graduate Periodontology clinic.  
The inclusion criteria of study participation included: (1) males or females between 
the age of 18 and 70 years (inclusive), (2) must be able and willing to follow study 
procedures and instructions, (3) must have read, understood and signed an informed 
consent form, (4) must be in good general health, (5) must have one or more implant 
placements as their future treatment needs, (6) must fit into one of the study groups as 
listed previously, and (7) must have probing depth ≤ 4 mm or 5mm without bleeding on 
probing for all teeth at the same quadrant of implant placement as determined by two 
calibrated examiners .  
Individuals were not enrolled into the study if they presented with the following 
exclusion criteria: (1) chronic disease with oral manifestations (e.g. Crohn’s disease, 
lupus erythematosus, Behcet’s disease), (2) gross oral pathology, (3) use of either 
antibiotics or NSAIDs within 2 weeks prior to screening examination, (4) chronic 
treatment (i.e. two weeks or more) with any medication known to affect periodontal 
status (e.g. phenytoin, calcium, antagonists, cyclosporin, warfarin) within 1 month prior 
to screening examination, (5) systemic conditions, except smoking and diabetes, that 
were known to affect the periodontal status, (6) active infectious diseases such as 
hepatitis, HIV or tuberculosis, and (7) known to be pregnant or breastfeeding.  
Recruited subjects must not present major changes in medical status during the 
entire study period for continuation of the protocol. There must have no infection at the 
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implant site for the entire duration of the study. Subjects not meeting this criterion would 
be withdrawn. Infection around an implant would be reported as an adverse event and 
subject would be followed until it was resolved.   
3. Clinical Study Method 
The following procedures were performed on study participants during a total of 5 
visits within a study period of 6-8 weeks.  
Visit 1 (≤ 2 weeks before implant surgery): 
• Study personnel obtained a signed written informed consent from the subject. 
• Study personnel obtained medical history and demographics related to the patient. 
• Study personnel performed HbA1C test on all subjects in the diabetic group (if a test 
result within past 3 months was not available). A drop of blood was obtained by finger 
prick and was loaded into a DCA 2000 HbA1C reagent cartridge, which was then 
processed immediately by a DCA 2000®+ Analyzer (Bayer Inc., Toronto, ON, 
Canada) for HbA1C level. 
• Patient vital signs (blood pressure and pulse), height and weight were recorded. 
• A dental examiner performed a general oral examination for presence of any 
abnormalities.   
• A dental examiner scored all teeth in the same quadrant of implant placement for 
plaque index, gingival index, probing depth, percent bleeding on probing and clinical 
attachment level.  
Visit 2 (Implant surgery): 
• Study personnel updated medical history and obtained vital signs. 
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• A dental examiner performed a general oral examination for presence of any 
abnormalities.   
• The dental examiner collected 8 GCF samples from the mesiolingual, mesiobuccal, 
distolingual and distobuccal surfaces of the two teeth that were in the closest 
proximity to the implant site. Samples were collected using filter paper strips (Pro 
Flow, Inc., Amityville, NY).  
• The dental examiner collected 1 biopsy at the site of implant placement for 
quantitative PCR, DNA methylation sequence analysis and differential methylation 
analysis. The biopsy sample was obtained with a 4mm punch biopsy blade or a 
scalpel blade. It was removed in the same way as how discarded tissues will be 
removed. It was removed at the beginning of the surgery as the clinician exposed the 
underlying bone at the implant site, or before suturing when the clinician reduced 
redundant tissues to achieve better flap closure.  
Visits 3-5 (2 weeks ± 2 days, 4 weeks ± 2 days, 6 weeks ± 2 days after surgery): 
• Study personnel updated medical history and obtained vital signs. 
• A dental examiner performed a general oral examination for presence of any 
abnormalities.   
• A dental examiner scored all teeth in the same quadrant of implant placement for 
plaque index and gingival index. 
• The dental examiner recorded wound healing indices (WHI) as indicators of degree 
of soft tissue healing for the implant site. 
• The dental examiner tested degree of osseointegration in terms of degree of implant 
stability using Osstell ISQ instrument. (Visit 4 and 5 only) 
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• The dental examiner collected 8 GCF samples in the same areas and using the same 
method as indicated previously. 
 
Table 5. Schedule of Procedures by Visit 
 
Week 
Visit 1 
-2 to -1 
Visit 2 
0 
Visit 3 
2 
Visit 4 
4 
Visit 5 
6 
Procedure:      
Informed Consent X     
Medical/Dental History X X X X X 
Demographics X     
Vital Signs X X X X X 
HbA1C Test (for diabetic group 
only) X     
Oral Examination X X X X X 
PI, GI X  X X X 
PD, BOP, CAL X     
WHI   X X X 
Implant Stability Measurement    X X 
Biopsy Sample  X    
GCF Sample  X X X X 
Saliva Sample  X X X X 
Adverse Experience X X X X X 
 
 
  
 
 
 
52	
	
4. Clinical Periodontal Assessments 
Clinical examiners were calibrated prior to commencement of the study. Clinical 
parameters assessed in the periodontal examination included plaque index, gingival index, 
probing depth, bleeding on probing, and clinical attachment level. Clinical parameters were 
measured using a manual University of North Carolina (UNC-15) periodontal probe. These 
parameters were measured at six periodontal sites per tooth (i.e., mesiobuccal, buccal, 
distobuccal, mesiolingual, lingual, and distolingual) and at all teeth in the same quadrant 
where implant placement is desired (including the third molar).  
Silness and Löe Plaque Index (PI) (SILNESS & LOE 1964):  
PI was defined as the relative amount of supragingival plaque and was recorded on 
an ordinal scale of 0-3.  
0- No plaque in the gingival area. 
1- A film of plaque adhering to the free gingival margin and the adjacent 
tooth. The plaque may be recognized only by running a probe across the 
tooth surface 
2- Moderate accumulation of soft deposits within the gingival pocket and on 
the gingival margin and/or adjacent tooth surface, which can be seen by 
the naked eye. 
3- Abundance of soft matter within the gingival pocket and/or on the gingival 
margin and the adjacent tooth surface.  
Löe and Silness Gingival Index (GI) (LOE & SILNESS 1963):  
GI was defined as the degree of gingival inflammation and was recorded on an 
ordinal scale of 0-3.  
53	
	
0- Normal gingiva. 
1- Mild inflammation (slight change in color, slight edema); no bleeding on 
palpation (i.e., sulcular sweep). 
2- Moderate inflammation (redness, edema, glazing); bleeding on palpation 
(i.e., sulcular sweep). 
4- Severe inflammation (i.e., marked redness, edema); ulceration, tendency 
to spontaneous bleeding. 
Probing depth (PD):  
PD was defined as the linear distance from the gingival margin (GM) to base of the 
pocket. If a PD reading fell between two millimeter readings, the rule was to round down 
and the lower of the two readings was recorded.  
Bleeding on Probing (BOP):  
BOP was defined as the presence or absence of bleeding to manual probing and was 
recorded as a dichotomous variable. 
0- No bleeding within 10 seconds after probing. 
1- Bleeding within 10 seconds after probing. 
Clinical attachment level (CAL):  
CAL was defined as the linear distance from the cemento-enamel junction (CEJ) to 
base of the pocket. If a CAL reading fell between two millimeter readings, the rule was to 
round down and the lower of the two readings was recorded.   
Wound healing indices (WHI): 
WHI was defined as the degree of soft tissue healing and consisted of four indices. 
Each index was recorded on an ordinal scale of 0-3.  
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Degree of Edema 
0- No gingival edema. 
1- Mild gingival edema. 
2- Moderate gingival edema. 
3- Severe gingival edema. 
Degree of Erythema 
0- No erythema. 
1- Mild erythema. 
2- Moderate erythema. 
3- Severe erythema. 
Degree of Pain on Palpation 
0- No pain. 
1- Mild pain. 
2- Moderate pain. 
3- Severe pain. 
Degree of Flap Closure 
0- No fibrin line or folding line in the incision area. 
1- Fine fibrin line or folding line in the incision area. 
2- Fibrin clot in the incision area. 
3- Partial or complete necrosis of flap.  
Implant Stability:  
Implant stability at 4 and 6 weeks after implant placement was measured with a 
device called Osstell ISQ instrument. This instrument used resonance frequency analysis 
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as a method to measure implant stability. It consisted of a wireless SmartPeg, a hand-held 
probe and the Osstell meter. The SmartPeg was first attached to the implant. The hand-
held probe then stimulated it magnetically. The displayed Implant Stability Quotient 
(ISQ) reflected the degree of stability. The scale ranged from 1 to 100. The higher the 
ISQ, the more stable the implant. The overall average value of all implants over time was 
approximately 70 ISQ.
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